Please login to the form below

Not currently logged in

Moderna to begin pivotal phase 3 trial of COVID-19 vaccine in July

Large-scale study will include 30,000 individuals

FDA delays review of Novartis’ MS drug ofatumumab

Novartis buildingRegulator now expected to deliver verdict on application in September

Sanofi makes ‘best-in-class’ claim for Sarclisa in myeloma

Sanofi receptionChallenges Johnson & Johnson’s Darzalex

ASCO: Momentum gathers behind next wave of CAR-T therapies

GileadUpdate from Gilead and new data from J&J, BMS and others

Lilly starts world first trial of an antibody drug for COVID-19

Drug is the first to be specifically designed to treat the virus

Pfizer’s Ibrance misses the mark in early breast cancer

Drug was unable to demonstrate statistical significance in primary endpoint

ASCO: Merck’s Keytruda tops chemo in MSI-H colorectal cancer

merck-keytruda-pembrolizumab-melanomaPD-1 inhibitor more than doubled progression-free survival compared to chemotherapy

ASCO: Bavencio boosts survival post-chemo in bladder cancer

BavencioMerck KGaA and Pfizer report drug reduces risk of death by 31%

IFPMA industry association conference: ‘no-one left behind’ on coronavirus vaccine

Coronavirus vaccineCEOs of vaccine giants AZ, GSK, J&J and Pfizer pledge to pull out all the stops

Q&A: Kay Wesley

PME chats to the Chief Executive of Kanga Health Ltd and Town Councillor at Women’s Equality Party Congleton

Latest appointments

COVID-19 Updates and Daily News

Featured jobs


Add my company

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....